On May 7, 2024, BioVersys AG closed the transaction. The company issued common shares for CHF 12.3 million in its third and final tranche, bringing a total funding of CHF 44.9 million in the transaction. The transaction included participation from new investor GSK plc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,775 GBX | -0.48% | -1.36% | +22.40% |
May. 17 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
May. 17 | Marti Technologies Hires Oguz Erkan as CFO | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.40% | 91.97B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- BioVersys AG announced that it has received CHF 44.9 million in funding from AMR Action Fund GP, LLC, GSK plc and other investor.